Recent Developments in the Treatment of Wet Age-related Macular Degeneration

Abstract

Age-related macular degeneration (AMD) is the most common cause of irreversible blindness and visual impairment in individuals over the age of 50 years in western societies. More than 25 million people currently suffer from this illness in the world, with an additional 500 000 every year, approximately. It is a multifactorial ocular disease that affects the maculae due to a late-onset progressive neurodegeneration and dysfunction of photoreceptors and retinal pigment epithelium (RPE). There are many subtypes of AMD but basically two broad forms: the nonneovascular (dry, nonexudative) and neovascular (wet, exudative). Exudative AMD is the less common form (about 15%) but tends to progress more rapidly. At the moment, wet AMD is treated primarily on the basis of anti-vascular endothelial growth factor (VEGF) agents, which have led to massive improvement in the prognosis of the disease since they were first introduced. This article focuses on the latest treatment approaches to neovascular AMD. An extensive literature review was performed in order to illustrate the effectiveness of current and future anti-VEGF agents as well as the landmark clinical studies that have been carried out to establish these drugs as a gold standard in the therapy of wet AMD.

Keywords

neovascular age-related macular degeneration / exudative AMD / medical retina / retinal diseases / neovascularization / angiogenesis / vascular endothelial growth factor

References

[1] YonekawaY, KimIK. Clinical characteristics and current treatment of age-related macular degeneration. Cold Spring Harb Perspect Med, 2015, 5(1): a017178

[2] VerittiD, SaraoV, LanzettaP. Neovascular age-related macular degeneration. Ophthalmologica, 2012, 227(Suppl.1): 11-20

[3] Yanoff M, Duker JS. Age-Related Macular Degeneration. Ophthalmology 4th edition. Elsevier Saunders. 2014:580–604.

[4] Kanski JJ, Bowling B. Acquired Macular Disorders. Clinical ophthalmology: a systematic approach 7th edition. Elsevier Health Sciences. 2011:594–646.

[5] Denniston A, Murray P, editors. Medical Retina. Oxford handbook of ophthalmology. OUP Oxford. 2014:515–592.

[6] Gerhard K. Lang. Retina. Ophthalmology: A Pocket Textbook Atlas. Thieme. 2007:305–372.

[7] Kanski JJ, Bowling B. Acquired Macular Disorders. Synopsis of Clinical Ophthalmology 3rd edition. Elsevier Health Sciences. 2013:268–287.

[8] García-LayanaA, FigueroaMS, AraizJ, et al.. Treatment of exudative age-related macular degeneration: focus on aflibercept. Drugs Aging, 2015, 32(10): 797-807

[9] Kanski JJ, Bowling B. Acquired Macular Disorders. Clinical ophthalmology: a systematic approach 8th edition. Elsevier Health Sciences. 2016:580–639.

[10] Coscas G. Optical coherence tomography in age-related macular degeneration. Springer Science & Business Media. 2009 Jul 25.

[11] MaJ, DesaiR, NesperP, et al.. Optical Coherence Tomographic Angiography Imaging in Age-Related Macular Degeneration. Ophthalmol Eye Dis, 2017, 9: 1179172116686075

[12] LyA, Nivison-SmithL, AssaadN, et al.. Fundus autofluorescence in age-related macular degeneration. Optometry Vis Sci, 2017, 94(2): 246

[13] PengQ, DongY, ZhaoPQ. Fundus autofluorescence in exudative age-related macular degeneration. Genet Mol Res, 2013, 12(4): 6140-6148

[14] ShaoJ, ChoudharyMM, SchachatAP. Neovascular age-related macular degeneration. Dev Ophthalmol, 2016, 55: 125-136

[15] Al-ZamilWM, YassinSA. Recent developments in age-related macular degeneration: a review. Clin Interv Aging, 2017, 12: 1313

[16] Petrarca R, Jackson TL. Radiation therapy for neovascular age-related macular degeneration. Clin Ophthalmol (Auckland, NZ). 2011,5:57

[17] JacksonTL, ChakravarthyU, KaiserPK, et al.. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study. Ophthalmology, 2013, 120(9): 1893-1900

[18] NeffendorfJE, JacksonTL. Stereotactic radiotherapy for wet age-related macular degeneration: current perspectives. Clin Ophthalmol (Auckland, NZ), 2015, 9: 1829

[19] PożarowskaD, PożarowskiP. The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy. Cent Eur J Immunol, 2016, 41(3): 311

[20] HassanM, AfridiR, SadiqMA, et al.. The role of Aflibercept in the management of age-related macular degeneration. Expert Opin Biol Ther, 2016, 16(5): 699-709

[21] BaJ, PengRS, XuD, et al.. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. Drug Des Dev Ther, 2015, 9: 5397-9405

[22] OhrM, KaiserPK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother, 2012, 13(4): 585-591

[23] BalaratnasingamC, Dhrami-GavaziE, McCannJT, et al.. Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration. Clin Ophthalmol (Auckland, NZ), 2015, 9: 2355

[24] PapadopoulosZ. Aflibercept: A review of its effect on the treatment of exudative age-related macular degeneration. Eur J Ophthalmol, 2019, 29(4): 368-378

[25] FramptonJE. Aflibercept for intravitreal injection. Drugs Aging, 2012, 29(10): 839-846

[26] FalavarjaniKG, NguyenQD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye, 2013, 27(7): 787-794

[27] CostagliolaC, AgnifiliL, ArcidiaconoB, et al.. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. Expert Opin Biol Ther, 2012, 12(10): 1299-1313

[28] RayessN, HoustonSSIII, GuptaOP, et al.. Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol, 2015, 159(1): 3-8

[29] Chin-YeeD, EckT, FowlerS, et al.. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol, 2016, 100(7): 914-917

[30] WykoffCC, CroftDE, BrownDM, et al.. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology, 2015, 122(12): 2514-2522

[31] WykoffCC, OuWC, BrownDM, et al.. Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD study. Ophthalmol Retina, 2017, 1(4): 314-321

[32] AugsburgerM, SarraGM, ImeschP. Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study. Graefes Arch Clin Exp Ophthalmol Graefes Arch Clin Exp Ophthalmol, 2019, 257(9): 1889-1895

[33] HolekampNM. Review of neovascular age-related macular degeneration treatment options. Am J Managed Care, 2019, 25(10Suppl): S172-181

[34] SharmaA, KumarN, KuppermannBD, et al.. Abicipar pegol: the non-monoclonal antibody anti-VEGF. Eye, 2019, 30: 1-5

[35] LuX, SunX. Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des, Dev Ther, 2015, 9: 2311-2320

[36] LiX, XuG, WangY, et al.. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology, 2014, 121(9): 1740-1747

[37] DugelPU, KohA, OguraY, et al.. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology, 2019, 127(1): 72-84

[38] MarkhamA. Brolucizumab: First Approval. Drugs, 2019, 79(18): 1997-2000

[39] Boxler D. Brolucizumab-dbll Approved by FDA for Wet AMD.

[40] YannuzziNA, FreundKB. Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration. Clin Ophthalmol (Auckland, NZ), 2019, 13: 1323-1329